Successful use of rituximab, an anti‐CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa

Successful use of rituximab, an anti‐CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa

We describe the successful use of rituximab for the treatment of IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa. To our knowledge, this is the first reported case in the literature.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental dermatology 2022-08, Vol.47 (8), p.1588-1590
Hauptverfasser: Hunjan, Manrup Kaur, Bardhan, Ajoy, Harper, Natasha, Langman, Gerald, Ajayi, Bamidele, Suresh, Vijay, Heagerty, Adrian H. M.
Format: Artikel
Sprache:eng
Schlagworte:
CD20 antigen
Dystrophic epidermolysis bullosa
Epidermolysis bullosa
IgA nephropathy
Immunoglobulin A
Immunotherapy
Monoclonal antibodies
Patients
Rituximab
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We describe the successful use of rituximab for the treatment of IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa. To our knowledge, this is the first reported case in the literature.
ISSN:0307-6938
1365-2230
DOI:10.1111/ced.15228